Fintel reports that on April 2, 2025, BTIG initiated coverage of NRx Pharmaceuticals (NasdaqCM:NRXP) with a Buy recommendation. Analyst Price Forecast Suggests 1,491.13% Upside As of April 2, 2025, ...

NRx Pharmaceuticals NRXP is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for NRXP’s loss per share is pinned at 20 cents. In the absence of a marketed ...

NRX-100 is poised to address the >$3 billion Suicidal Depression market in the US. The Company has accepted non-binding potential terms from a commercial pharmaceutical company to license and ...

Good morning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals 4Q and Full Year 2024 Earnings Call. At this time, all lines are in a listen only mode. Following the presentation ...

NRx Pharmaceuticals has a twelve month low of $1.10 and a twelve month high of $6.01. The stock has a market capitalization of $34.68 million, a PE ratio of -0.96 and a beta of 1.22.

Shares of NRx Pharmaceuticals, Inc. (NRXP) have been struggling lately and have lost 5.1% over the past week. However, a hammer chart pattern was formed in its last trading session, which could ...

BTIG initiated coverage of NRx Pharmaceuticals (NRXP) with a Buy rating and $18 price target NRx Pharmaceuticals is working broadly in suicidal ideation and behavior, a large area of unmet need ...

Hope Therapeutics, an interventional psychiatry network wholly owned by NRx Pharmaceuticals (NRXP), announced signing of a definitive agreement ...

NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report)‘s stock had its “buy” rating reaffirmed by D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports.